The relationship between HBsAg carrier state and hepatotoxicity during anti-tuberculosis chemotherapy

Abstract

Abstract: Objective To determine whether inactive hepatitis B surface antigen(HBsAg) carriers are at a higher risk of drug-induced hepatotoxicity than control subjects during anti-tuberculosis treatment.Methods One hundred fifty-six inactive HBsAg carriers with newly diagnosed active tuberculosis who received standard anti-tuberculosis treatment were included in the study population.One hundred forty-one HBsAg negative patients who received standard anti-tuberculosis treatment were selected as control subjects.Results More severe hepatotoxicities were observed in cases than controls.After the hepatotoxicity was cured,HBsAg carriers can be treated with isoniazid,rifampin,ethambutol,and/or pyrazinamide again.Conclusion With monthly liver function examination,it is effective and safe for TB and non-active HBV co-infected patients to be treated with standard short-course regimens.

Key words: Anti-tuberculosis drug, Hepatotoxicity, Hepatitis B

Chen Zhifei,Han Dan,Sun Xuezhi. The relationship between HBsAg carrier state and hepatotoxicity during anti-tuberculosis chemotherapy[J]. Chinese Journal of Antituberculosis, 2007, 29(4): 343-346.

References

1 Blumberg HM,Burman WJ, Chaisson RE, et al. American Thoracic So-ciety/Centers for Disease Control and Prevention/Infectious Diseases So-ciety of America ： treatment of tuberculosis [J].Am J Respir Crit CareMed, 2003, 167(4)：603
2 Pande JN, Singh SP, Khilnani GC, et al. Risk factors for hepatotoxicity from antituberculosis drugs： a case-control study[J]. Thorax, 1996, 51(2)：132
3 Dossing M, Wilcke JT, Askgaard DS, et al. Liver injury during antitu-berculosis treatment: an 11-year study [J]. Tuber Lung Dis, 1996 , 77(4)：335
4 McGlynn KA, Lustbader ED, Sharrar RG, et al. Isoniazid prophylaxis in hepatitis B carriers[J]. Am Rev Respir Dis, 1986,134(4)：666
5 Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States [J]. Am J Gastroenterol, 2002, 97(5)：1198
6 Wu JC, Lee SD, Yeh PF, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers[J]. Gastroenterology, 1990 , 98(2)：502
7 Amarapurkar DN, Prabhudesai PP, Kalro RH, et al. Antituberculosis drug-induced hepatitis and HBsAg carriers [J] . Tuber Lung Dis, 1993,74(3):215
8 Hwang SJ, Wu JC, Lee CN，et al. A prospective clinical study of isoni-azid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B[J]. J Gastroenterol Hepatol, 1997, 12(1):87
9 Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection [J] . Hepatology, 2000, 31(1):201
10 何国钧.抗结核化疗的进展与存在问题浅议[J].中华结核和呼吸杂志，1993,16(2):67
11 Lok AS, McMahon BJ. Chronic hepatitis B[J]. Hepatology, 2001, 34(6):1225
12 Ungo JR, Jones D, Ashkin D, et al. Antituberculosis druginduced hep-atotoxicity ：the role of hepatitis C virus and the human immunodeficiency virus[J]. Am J Respir Crit Care Med, 1998, 157(6 pt 1)：1871
13 Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis[J]. Am J Respir Crit Care Med, 2003, 167(11)：1472
14 Parthasarathy R, Sarma GR, Janardhanam B, et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid v rifampicin and pyrazinamide [J]. Tuber-cle, 1986, 67(2)：99
15 Turktas H，Unsal M, Tulek N, et al. Hepatotoxicity of antituberculosis therapy ( rifampicin, isoniazid and pyrazinamide) or viral hepatitis [J].Tuber Lung Dis, 1994, 75(1):58

[1]	LAI Xiao-yu，HUANG Pei-sheng，LIU Gui-fen. Effects of positive hepatitis B surface antigen on liver injury induced by anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2015, 37(2): 173-177.
[2]	DENG Guo-fang, SUN Li-zhen, LEI Jian-ping, WU Yu-qing, YE Hong. Clinical analysis of lamivudine combined with anti-tuberculosis drugs in treating pulmonary tuberculosis complicated with hepatitis B virus carriers [J]. Chinese Journal of Antituberculosis, 2014, 36(2): 104-108.
[3]	ZHANG Xi-lin, HUANG Dan, WU Yan-ting, CHEN Xiao-yan. Clinical research of different regimens in patients with pulmonary tuberculosis combined with type B hepatitis [J]. Chinese Journal of Antituberculosis, 2011, 33(9): 578-581.
[4]	Weng Lizhen,Zhu Yufang,Chen Shuqin,et al.. Clinical observation on the clinical efficacy of compound Glycyrrhizin in the treatment of new pulmonary tuberculosis complicated with chronic hepatitis B [J]. Chinese Journal of Antituberculosis, 2007, 29(5): 419-422.
[5]	Wang Qingfeng,Song Yanhua,Gao Mengqiu,et al.. Clinical analysis on 368 pulmonary tuberculosis cases with hepatic lesion caused by anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2007, 29(3): 252-255.
[6]	Xu Jintian. Analysis of the therapeatical effect of levofloxacin on superficial lymphous tuberculosis [J]. Chinese Journal of Antituberculosis, 2007, 29(3): 247-249.
[7]	Xiong Guojiang,Xiong Guoliang,Xiong Hanpeng.. The clinical value of measuring HBVDNA for pulmonary tuberculosis patients with HBVM positive [J]. Chinese Journal of Antituberculosis, 2006, 28(6): 408-410.
[8]	Tan Shouyong,Lin Zhaoyua,Guan Yuhuan,et al.. The protein-malnutrition and drug-induced hepatitis due to anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2006, 28(2): 83-86.
[9]	Zhu Yuyin,Zheng Chunyu,Ye Chunjuan,et al.. The impaet of HBVM positive to hepatic function and relative countermeasure [J]. Chinese Journal of Antituberculosis, 2004, 26(1): 50-52.
[10]	MENG Zhi-hao.. Effect of antituberculosis drugs on liver functions of the tuberculosis patient complicated with both hepatitis B and hepatitis C virus infectious [J]. Chinese Journal of Antituberculosis, 2003, 25(5): 318-320.
[11]	CHEN Si cang,CHEN Hong qi.. Obervation of the effect on liver function in pulmonay tuberculosis with positive HBVM treated by antituberculotic combination [J]. Chinese Journal of Antituberculosis, 2001, 23(1): 30-32.
[12]	ZHU Jie,SHI Nan-feng,CEN Long-gen.. The observation of curative effect of IL-2 supplemented with short-course chemotherapy for 50 cases of smear-positive pulmonary tuberculosls accompanying hepatitis B [J]. Chinese Journal of Antituberculosis, 2000, 22(4): 222-224.